Toll-like receptor 4 modulation as a strategy to treat sepsis

Mediators of Inflammation

Volumn 2010, Issue , 2010, Pages

  Wittebole, X ^a   Castanares Zapatero, D ^a   Laterre, P F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CHLOROQUINE; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; CYTOKINE; E 5531; ENDOTOXIN; ERITORAN; GLYCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; KETAMINE; LIDOCAINE; MESSENGER RNA; MORPHINE; NICOTINE; NICOTINE DERIVATIVE; OPIATE DERIVATIVE; PLACEBO; PROTEIN ANTIBODY; PROTON PUMP INHIBITOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR 4 ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR; 3 O DECYL 2 DEOXY 6 O (2 DEOXY 3 O (3 METHOXYDECYL) 6 O METHYL 2 ((1 OXO 11 OCTADECENYL)AMINO) 4 O PHOSPHONOGLUCOPYRANOSYL) 2 ((1,3 DIOXOTETRADECYL)AMINO) 1 (DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; 3-O-DECYL-2-DEOXY-6-O-(2-DEOXY-3-O-(3-METHOXYDECYL)-6-O-METHYL-2-((1-OXO-11-OCTADECENYL)AMINO)-4-O-PHOSPHONOGLUCOPYRANOSYL)-2-((1,3-DIOXOTETRADECYL)AMINO)-1-(DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; ANALGESIC AGENT; ANTIBODY; ANTIRHEUMATIC AGENT; DISACCHARIDE; DRUG DERIVATIVE; ETHYL 6 (N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL)CYCLOHEX 1 ENE 1 CARBOXYLATE; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; GANGLION STIMULATING AGENT; LY96 PROTEIN, HUMAN; NARCOTIC ANALGESIC AGENT; PROTEIN MD 2; SUGAR PHOSPHATE; SULFONAMIDE; TLR4 PROTEIN, HUMAN;

ADJUVANT THERAPY; CHRONIC PAIN; CLINICAL TRIAL; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; DUODENUM ULCER; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE BACTERIUM; HUMAN; LUNG INJURY; MALARIA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REFLUX ESOPHAGITIS; REVIEW; SEPSIS; SEPTIC SHOCK; STOMACH ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY;

NEGIBACTERIA;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ANTIBODIES; ANTIRHEUMATIC AGENTS; CHLOROQUINE; CHOLECALCIFEROL; DISACCHARIDES; GANGLIONIC STIMULANTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KETAMINE; LYMPHOCYTE ANTIGEN 96; NICOTINE; SEPSIS; SUGAR PHOSPHATES; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 77952481566     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2010/568396     Document Type: Review

References (94)

1. Friedman G., Silva E., Vincent J.-L., Has the mortality of septic shock changed with time? Critical Care Medicine 1998 26 12 2078 2086
2. Martin G. S., Mannino D. M., Eaton S., Moss M., The epidemiology of sepsis in the United States from 1979 through 2000 New England Journal of Medicine 2003 348 16 1546 1554
3. Vincent J.-L., Sakr Y., Sprung C. L., Sepsis Occurrence in acutely Ill patients investigators. Sepsis in European intensive care units: results of the SOAP study Critical Care Medicine 2006 34 2 344 353
4. Medzhitov R., Preston-Hurlburt P., Janeway C. A. Jr., A human homologue of the Drosophila toll protein signals activation of adaptive immunity Nature 1997 388 6640 394 397
5. Poltorak A., He X., Smirnova I., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 1998 282 5396 2085 2088
6. Hoshino K., Takeuchi O., Kawai T., Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide evidence for TLR4 as the Lps gene product Journal of Immunology 1999 162 7 3749 3752
7. Lemaitre B., Nicolas E., Michaut L., Reichhart J.-M., Hoffmann J. A., The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in Drosophila adults Cell 1996 86 6 973 983
8. Medzhitov R., Toll-like receptors and innate immunity Nature Reviews Immunology 2001 1 2 135 145
9. Takeda K., Akira S., Toll-like receptors in innate immunity International Immunology 2005 17 1 1 14
10. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity Cell 2006 124 4 783 801
11. Tsujimoto H., Ono S., Efron P. A., Scumpia P. O., Moldawer L. L., Mochizuki H., Role of Toll-like receptors in the development of sepsis Shock 2008 29 3 315 321
12. Salomo R., Martins P. S., Brunialti M. K. C., TLR signaling pathway in patients with sepsis Shock 2008 30 supplement 1 73 76
13. Weighardt H., Holzmann B., Role of Toll-like receptor responses for sepsis pathogenesis Immunobiology 2008 212 9-10 715 722
14. Miyake K., Yamashita Y., Hitoshi Y., Takatsu K., Kimoto M., Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells Journal of Experimental Medicine 1994 180 4 1217 1224
15. Miyake K., Shimazu R., Kondo J., Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression Journal of Immunology 1998 161 3 1348 1353
16. Divanovic S., Trompette A., Atabani S. F., Inhibition of TLR-4/MD-2 signaling by RP105/MD-1 Journal of Endotoxin Research 2005 11 6 363 368
17. Divanovic S., Trompette A., Atabani S. F., Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105 Nature Immunology 2005 6 6 571 578
18. Wittebole X., Coyle S. M., Kumar A., Goshima M., Lowry S. F., Calvano S. E., Expression of tumour necrosis factor receptor and Toll-like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of flow cytometric light scatter and immunofluorescence gating Clinical and Experimental Immunology 2005 141 1 99 106
19. Hrter L., Mica L., Stocker R., Trentz O., Keel M., Increased expression of Toll-like receptor-2 and-4 on leukocytes from patients with sepsis Shock 2004 22 5 403 409
20. Brandl K., Glck T., Huber C., Salzberger B., Falk W., Hartmann P., TLR-4 surface display on human monocytes is increased in septic patients European Journal of Medical Research 2005 10 8 319 324
21. Rogy M. A., Coyle S. M., Oldenburg H. S. A., Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients Journal of the American College of Surgeons 1994 178 2 132 138
22. Iwami K.-I., Matsuguchi T., Masuda A., Kikuchi T., Musikacharoen T., Yoshikai Y., Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling Journal of Immunology 2000 165 12 6682 6686
23. Roger T., Froidevaux C., Le Roy D., Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4 Proceedings of the National Academy of Sciences of the United States of America 2009 106 7 2348 2352
24. Gro P., Brandl K., Dierkes C., Lipopolysaccharide-Trap-Fc, a multifunctional agent to battle gram-negative bacteria Infection and Immunity 2009 77 7 2925 2931
25. Christ W. J., Asano O., Robidoux A. L. C., E5531, a pure endotoxin antagonist of high potency Science 1995 268 5207 80 83
26. Bunnell E., Lynn M., Habet K., A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia Critical Care Medicine 2000 28 8 2713 2720
27. Wasan K. M., Strobel F. W., Parrott S. C., Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels Antimicrobial Agents and Chemotherapy 1999 43 10 2562 2564
28. Rose J. R., Mullarkey M. A., Christ W. J., Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins Antimicrobial Agents and Chemotherapy 2000 44 3 504 510
29. Hawkins L. D., Christ W. J., Rossignol D. P., Inhibition of endotoxin response by synthetic TLR4 antagonists Current Topics in Medicinal Chemistry 2004 4 11 1147 1171
30. Mullarkey M., Rose J. R., Bristol J., Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist Journal of Pharmacology and Experimental Therapeutics 2003 304 3 1093 1102
31. Kim H. M., Park B. S., Kim J.-I., Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran Cell 2007 130 5 906 917
32. Mullarkey M., Rose J. R., Bristol J., Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist Journal of Pharmacology and Experimental Therapeutics 2003 304 3 1093 1102
33. Czeslick E., Struppert A., Simm A., Sablotzki A., E5564 (eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes Inflammation Research 2006 55 11 511 515
34. Rossignol D. P., Wong N., Noveck R., Lynn M., Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers Innate Immunity 2008 14 6 383 394
35. Lynn M., Rossignol D. P., Wheeler J. L., Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia Journal of Infectious Diseases 2003 187 4 631 639
36. Tidswell M., Tillis W., Larosa S. P., Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis Critical Care Medicine 2010 38 1 72 83
37. Frantz S., Kobzik L., Kim Y.-D., Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium Journal of Clinical Investigation 1999 104 3 271 280
38. Baumgarten G., Knuefermann P., Schuhmacher G., Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia Shock 2006 25 1 43 49
39. Ehrentraut S., Frede S., Stapel H., Antagonism of lipopolysaccharide- induced blood pressure attenuation and vascular contractility Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 10 2170 2176
40. Shimamoto A., Chong A. J., Yada M., Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury Circulation 2006 114 supplement 1 I270 I274
41. Bennett-Guerrero E., Grocott H. P., Levy J. H., A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass Anesthesia and Analgesia 2007 104 2 378 383
42. Yamada M., Ichikawa T., Ii M., Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex- 1-ene-1-carboxylate Journal of Medicinal Chemistry 2005 48 23 7457 7467
43. Ii M., Matsunaga N., Hazeki K., A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling Molecular Pharmacology 2006 69 4 1288 1295
44. Kawamoto T., Ii M., Kitazaki T., Iizawa Y., Kimura H., TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain European Journal of Pharmacology 2008 584 1 40 48
45. Takashima K., Matsunaga N., Yoshimatsu M., Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model British Journal of Pharmacology 2009 157 7 1250 1262
46. Sha T., Sunamoto M., Kitazaki T., Sato J., Ii M., Iizawa Y., Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model European Journal of Pharmacology 2007 571 2-3 231 239
47. Kuno M., Nemoto K., Ninomiya N., The novel selective Toll-like receptor 4 signal transduction inhibitor tak-242 prevents endotoxaemia in conscious guinea-pigs Clinical and Experimental Pharmacology and Physiology 2009 36 5-6 589 593
48. Kitchens R. L., Wang P.-Y., Munford R. S., Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways Journal of Immunology 1998 161 10 5534 5545
49. Thieblemont N., Wright S. D., Transport of bacterial lipopolysaccharide to the Golgi apparatus Journal of Experimental Medicine 1999 190 4 523 534
50. Zhou H., Ding G., Liu W., Lipopolysaccharide could be internalized into human peripheral blood mononuclear cells and elicit TNF-α release, but not via the pathway of Toll-like receptor 4 on the cell surface Cellular Molecular Immunology 2004 1 5 373 377
51. Park B., Brinkmann M. M., Spooner E., Lee C. C., Kim Y.-M., Ploegh H. L., Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9 Nature Immunology 2008 9 12 1407 1414
52. Sepulveda F. E., Maschalidi S., Colisson R., Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells Immunity 2009 31 5 737 748
53. Karres I., Kremer J.-P., Dietl I., Steckholzer U., Jochum M., Ertel W., Chloroquine inhibits proinflammatory cytokine release into human whole blood American Journal of Physiology 1998 274 4 43-4 R1058 R1064
54. Hong Z., Jiang Z., Liangxi W., Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release International Immunopharmacology 2004 4 2 223 234
55. Yasuda H., Leelahavanichkul A., Tsunoda S., Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury American Journal of Physiology 2008 294 5 F1050 F1058
56. Yu M., Shao D., Yang J., Feng S., Xu J., Ketamine suppresses intestinal TLR4 expression and NF-κB activity in lipopolysaccharide-treated rats Croatian Medical Journal 2006 47 6 825 831
57. Yu M., Shao D., Feng X., Duan M., Xu J., Effects of ketamine on pulmonary TLR4 expression and NF--B activation during endotoxemia in rats Methods and Findings in Experimental and Clinical Pharmacology 2007 29 6 395 399
58. Yu M., Shao D., Liu J., Zhu J., Zhang Z., Xu J., Effects of ketamine on levels of cytokines, NF-κB and TLRs in rat intestine during CLP-induced sepsis International Immunopharmacology 2007 7 8 1076 1082
59. Yu M., Shao D., Yang R., Feng X., Zhu S., Xu J., Effects of ketamine on pulmonary inflammatory responses and survival in rats exposed to polymicrobial sepsis Journal of Pharmacy Pharmaceutical Sciences 2007 10 4 434 442
60. Chen T.-L., Chang C.-C., Lin Y.-L., Ueng Y.-F., Chen R.-M., Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells Toxicology and Applied Pharmacology 2009 240 1 15 25
61. Chang H. C., Lin K. H., Tai Y. T., Chen J. T., Chen R. M., Lipoteichoic acid-induced TNF-α and IL-6 gene expressions and oxidative stress production in macrophages are suppressed by ketamine through downregulating Toll-like receptor 2-mediated activation of ERK1/2 and NF B. Shock. In press
62. Borovikova L. V., Ivanova S., Zhang M., Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin Nature 2000 405 6785 458 462
63. Wittebole X., Hahm S., Coyle S. M., Kumar A., Calvano S. E., Lowry S. F., Nicotine exposure alters in vivo human responses to endotoxin Clinical and Experimental Immunology 2007 147 1 28 34
64. Wang H., Yu M., Ochani M., Nicotinic acetylcholine receptor 7 subunit is an essential regulator of inflammation Nature 2003 421 6921 384 388
65. de Jonghe W. J., van der Zanden E. P., The F. O., Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2/STAT3 signaling pathway Nature Immunology 2005 6 844 851
66. Yoshikawa H., Kurokawa M., Ozaki N., Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-B phosphorylation and nuclear factor-B transcriptional activity through nicotinic acetylcholine receptor 7 Clinical and Experimental Immunology 2006 146 1 116 123
67. Kox M., van Velzen J. F., Pompe J. C., Hoedemaekers C. W., van der Hoeven J. G., Pickkers P., GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation Biochemical Pharmacology 2009 78 7 863 872
68. Hamano R., Takahashi H. K., Iwagaki H., Yoshino T., Nishibori M., Tanaka N., Stimulation of 7 nicotinic acetylcholine receptor inhibits CD14 and the Toll-like receptor 4 expression in human monocytes Shock 2006 26 4 358 364 (Pubitemid 44402020)
69. Bsibsi M., Ravid R., Gveric D., Van Noort J. M., Broad expression of Toll-like receptors in the human central nervous system Journal of Neuropathology and Experimental Neurology 2002 61 11 1013 1021
70. Sacerdote P., Opioid-induced immunosuppression Current Opinion in Supportive and Palliative Care 2008 2 1 14 18
71. Guo L.-H., Schluesener H. J., The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors Cellular and Molecular Life Sciences 2007 64 9 1128 1136
72. Hutchinson M. R., Zhang Y., Shridhar M., Evidence that opioids may have Toll-like receptor 4 and MD-2 effects Brain, Behavior, and Immunity 2010 24 1 83 95
73. + monocytes Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 7 1439 1445
74. Niessner A., Steiner S., Speidl W. S., Simvastatin suppresses endotoxin-induced upregulation of Toll-like receptors 4 and 2 in vivo Atherosclerosis 2006 189 2 408 413
75. Foldes G., von Haehling S., Okonko D. O., Jankowska E. A., Poole-Wilson P. A., Anker S. D., Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure International Journal of Cardiology 2008 124 1 80 85
76. Boekholdt S. M., Agema W. R. P., Peters R. J. G., Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events Circulation 2003 107 19 2416 2421
77. Hodgkinson C. P., Ye S., Statins inhibit Toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression Pharmacogenetics and Genomics 2008 18 9 803 813
78. Kirsch C., Eckert G. P., Mueller W. E., Statin effects on cholesterol micro-domains in brain plasma membranes Biochemical Pharmacology 2003 65 5 843 856
79. Tleyjeh I. M., Kashour T., Hakim F. A., Statins for the prevention and treatment of infections: a systematic review and meta-analysis Archives of Internal Medicine 2009 169 18 1658 1667
80. Brown A. J., Dusso A., Slatopolsky E., Vitamin D American Journal of Physiology 1999 277 2 46-2 F157 F175
81. Horiuchi H., Nagata I., Komoriya K., Protective effect of vitamin D3 analogues on endotoxin shock in mice Agents and Actions 1991 33 3-4 343 348
82. Moller S., Laigaard F., Olgaard K., Hemmingsen C., Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis International Journal of Medical Sciences 2007 4 4 190 195
83. Liu P. T., Stenger S., Li H., Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response Science 2006 311 5768 1770 1773
84. Sorensen O. E., Follin P., Johnsen A. H., Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3 Blood 2001 97 12 3951 3959
85. Zanetti M., Cathelicidins, multifunctional peptides of the innate immunity Journal of Leukocyte Biology 2004 75 1 39 48
86. Sadeghi K., Wessner B., Laggner U., Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns European Journal of Immunology 2006 36 2 361 370
87. Equils O., Naiki Y., Shapiro A. M., 1,25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells Clinical and Experimental Immunology 2006 143 1 58 64
88. Jeng L., Yamshchikov A. V., Judd S. E., Alterations in vitamin D status and antimicrobial peptide levels in patients in the intensive care unit with sepsis Journal of Translational Medicine 2009 7 28
89. Handa O., Yoshida N., Fujita N., Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors Inflammation Research 2006 55 11 476 482
90. Ohara T., Kanoh Y., Yoshino K., Kitajima M., Effects of lansoprazole on the lipopolysaccharide-stimulated Toll-like receptor 4 signal transduction systems: a study using the 293hTLR4/MD2-CD14 cells Journal of Clinical Biochemistry and Nutrition 2009 45 2 241 247
91. Huang Y.-H., Tsai P.-S., Kai Y.-F., Yang C.-H., Huang C.-J., Lidocaine inhibition of inducible nitric oxide synthase and cationic amino acid transporter-2 transcription in activated murine macrophages may involve voltage-sensitive Na+ channel Anesthesia and Analgesia 2006 102 6 1739 1744
92. Lee P.-Y., Tsai P.-S., Huang Y.-H., Huang C.-J., Inhibition of Toll-like receptor-4, nuclear factor-B and mitogen-activated protein kinase by lignocaine may involve voltage-sensitive sodium channels Clinical and Experimental Pharmacology and Physiology 2008 35 9 1052 1058
93. Feng G., Liu S., Wang G.-L., Liu G.-J., Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting NF-κB activation Pharmacology 2007 81 1 32 40
94. Wang H.-D., Lu D.-X., Qi R.-B., Therapeutic strategies targeting the LPS signaling and cytokines Pathophysiology 2009 16 4 291 296